A randomized, placebo-controlled trial of latrepirdine in Huntington disease
K Kieburtz, MP McDermott, TS Voss… - Archives of …, 2010 - jamanetwork.com
Objectives To evaluate the safety and tolerability of latrepirdine in Huntington disease (HD)
and explore its effects on cognition, behavior, and motor symptoms. Design Double-blind,
randomized, placebo-controlled trial. Setting Multicenter outpatient trial. Participants Ninety-
one participants with mild to moderate HD enrolled at 17 US and UK centers from July 18,
2007, through July 16, 2008. Intervention Latrepirdine, 20 mg 3 times daily (n= 46), or
matching placebo (n= 45) for a 90-day treatment period. Main Outcome Measures The …
and explore its effects on cognition, behavior, and motor symptoms. Design Double-blind,
randomized, placebo-controlled trial. Setting Multicenter outpatient trial. Participants Ninety-
one participants with mild to moderate HD enrolled at 17 US and UK centers from July 18,
2007, through July 16, 2008. Intervention Latrepirdine, 20 mg 3 times daily (n= 46), or
matching placebo (n= 45) for a 90-day treatment period. Main Outcome Measures The …
